JP2008509912A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008509912A5 JP2008509912A5 JP2007525749A JP2007525749A JP2008509912A5 JP 2008509912 A5 JP2008509912 A5 JP 2008509912A5 JP 2007525749 A JP2007525749 A JP 2007525749A JP 2007525749 A JP2007525749 A JP 2007525749A JP 2008509912 A5 JP2008509912 A5 JP 2008509912A5
- Authority
- JP
- Japan
- Prior art keywords
- optionally substituted
- substituted
- heterocyclyl
- heteroaryl
- aralkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims 673
- PIGFYZPCRLYGLF-UHFFFAOYSA-N Aluminum nitride Chemical compound [Al]#N PIGFYZPCRLYGLF-UHFFFAOYSA-N 0.000 claims 264
- 125000000623 heterocyclic group Chemical group 0.000 claims 188
- 125000001072 heteroaryl group Chemical group 0.000 claims 185
- 125000001424 substituent group Chemical group 0.000 claims 162
- 125000003710 aryl alkyl group Chemical group 0.000 claims 159
- 125000004475 heteroaralkyl group Chemical group 0.000 claims 159
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 claims 151
- 125000004415 heterocyclylalkyl group Chemical group 0.000 claims 151
- 125000005843 halogen group Chemical group 0.000 claims 150
- 125000004093 cyano group Chemical group *C#N 0.000 claims 126
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 121
- 125000000217 alkyl group Chemical group 0.000 claims 113
- 125000003118 aryl group Chemical group 0.000 claims 112
- 125000000753 cycloalkyl group Chemical group 0.000 claims 110
- 125000001188 haloalkyl group Chemical group 0.000 claims 102
- 125000002577 pseudohalo group Chemical group 0.000 claims 97
- 229910052739 hydrogen Inorganic materials 0.000 claims 67
- 239000001257 hydrogen Substances 0.000 claims 67
- 125000003107 substituted aryl group Chemical group 0.000 claims 60
- 125000005346 substituted cycloalkyl group Chemical group 0.000 claims 57
- 125000000547 substituted alkyl group Chemical group 0.000 claims 51
- 125000005017 substituted alkenyl group Chemical group 0.000 claims 48
- 239000000203 mixture Substances 0.000 claims 45
- 125000003342 alkenyl group Chemical group 0.000 claims 43
- 125000000304 alkynyl group Chemical group 0.000 claims 43
- 125000004426 substituted alkynyl group Chemical group 0.000 claims 43
- 150000001875 compounds Chemical class 0.000 claims 42
- 229910052717 sulfur Inorganic materials 0.000 claims 39
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 35
- 150000002431 hydrogen Chemical class 0.000 claims 32
- 102000004311 liver X receptors Human genes 0.000 claims 30
- 108090000865 liver X receptors Proteins 0.000 claims 30
- 229910052760 oxygen Inorganic materials 0.000 claims 30
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 28
- 229910052757 nitrogen Inorganic materials 0.000 claims 23
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 22
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims 14
- 201000010099 disease Diseases 0.000 claims 13
- 201000001320 Atherosclerosis Diseases 0.000 claims 11
- 208000035475 disorder Diseases 0.000 claims 11
- 239000004031 partial agonist Substances 0.000 claims 11
- 239000000556 agonist Substances 0.000 claims 10
- 125000002947 alkylene group Chemical group 0.000 claims 10
- 239000003795 chemical substances by application Substances 0.000 claims 10
- 125000004449 heterocyclylalkenyl group Chemical group 0.000 claims 10
- 239000012190 activator Substances 0.000 claims 9
- 239000013543 active substance Substances 0.000 claims 9
- 239000005557 antagonist Substances 0.000 claims 9
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 claims 9
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims 8
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 8
- 229940107161 cholesterol Drugs 0.000 claims 7
- 108010041872 Islet Amyloid Polypeptide Proteins 0.000 claims 6
- 102000036770 Islet Amyloid Polypeptide Human genes 0.000 claims 6
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 claims 6
- JFDZBHWFFUWGJE-UHFFFAOYSA-N benzenecarbonitrile Natural products N#CC1=CC=CC=C1 JFDZBHWFFUWGJE-UHFFFAOYSA-N 0.000 claims 6
- 239000003613 bile acid Substances 0.000 claims 6
- 230000015572 biosynthetic process Effects 0.000 claims 6
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 claims 6
- 229960003692 gamma aminobutyric acid Drugs 0.000 claims 6
- 239000003112 inhibitor Substances 0.000 claims 6
- DHHVAGZRUROJKS-UHFFFAOYSA-N phentermine Chemical compound CC(C)(N)CC1=CC=CC=C1 DHHVAGZRUROJKS-UHFFFAOYSA-N 0.000 claims 6
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 6
- HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 claims 5
- 125000000031 ethylamino group Chemical group [H]C([H])([H])C([H])([H])N([H])[*] 0.000 claims 5
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 5
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims 4
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims 4
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 claims 4
- 208000035150 Hypercholesterolemia Diseases 0.000 claims 4
- 208000031226 Hyperlipidaemia Diseases 0.000 claims 4
- 102000004877 Insulin Human genes 0.000 claims 4
- 108090001061 Insulin Proteins 0.000 claims 4
- 238000010521 absorption reaction Methods 0.000 claims 4
- 239000002876 beta blocker Substances 0.000 claims 4
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 claims 4
- 208000006575 hypertriglyceridemia Diseases 0.000 claims 4
- 229940125396 insulin Drugs 0.000 claims 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- DBGIVFWFUFKIQN-VIFPVBQESA-N (+)-Fenfluramine Chemical compound CCN[C@@H](C)CC1=CC=CC(C(F)(F)F)=C1 DBGIVFWFUFKIQN-VIFPVBQESA-N 0.000 claims 3
- DBGIVFWFUFKIQN-UHFFFAOYSA-N (+-)-Fenfluramine Chemical compound CCNC(C)CC1=CC=CC(C(F)(F)F)=C1 DBGIVFWFUFKIQN-UHFFFAOYSA-N 0.000 claims 3
- OGNSCSPNOLGXSM-UHFFFAOYSA-N (+/-)-DABA Natural products NCCC(N)C(O)=O OGNSCSPNOLGXSM-UHFFFAOYSA-N 0.000 claims 3
- RBCOYOYDYNXAFA-UHFFFAOYSA-L (5-hydroxy-4,6-dimethylpyridin-3-yl)methyl phosphate Chemical compound CC1=NC=C(COP([O-])([O-])=O)C(C)=C1O RBCOYOYDYNXAFA-UHFFFAOYSA-L 0.000 claims 3
- ILPUOPPYSQEBNJ-UHFFFAOYSA-N 2-methyl-2-phenoxypropanoic acid Chemical class OC(=O)C(C)(C)OC1=CC=CC=C1 ILPUOPPYSQEBNJ-UHFFFAOYSA-N 0.000 claims 3
- 239000005541 ACE inhibitor Substances 0.000 claims 3
- 239000000275 Adrenocorticotropic Hormone Substances 0.000 claims 3
- 229940077274 Alpha glucosidase inhibitor Drugs 0.000 claims 3
- 229940123413 Angiotensin II antagonist Drugs 0.000 claims 3
- XNCOSPRUTUOJCJ-UHFFFAOYSA-N Biguanide Chemical compound NC(N)=NC(N)=N XNCOSPRUTUOJCJ-UHFFFAOYSA-N 0.000 claims 3
- 229940123208 Biguanide Drugs 0.000 claims 3
- 102000013585 Bombesin Human genes 0.000 claims 3
- 108010051479 Bombesin Proteins 0.000 claims 3
- 208000024172 Cardiovascular disease Diseases 0.000 claims 3
- 206010008635 Cholestasis Diseases 0.000 claims 3
- 229940122502 Cholesterol absorption inhibitor Drugs 0.000 claims 3
- 101800000414 Corticotropin Proteins 0.000 claims 3
- 102000019432 Galanin Human genes 0.000 claims 3
- 101800002068 Galanin Proteins 0.000 claims 3
- HEMJJKBWTPKOJG-UHFFFAOYSA-N Gemfibrozil Chemical compound CC1=CC=C(C)C(OCCCC(C)(C)C(O)=O)=C1 HEMJJKBWTPKOJG-UHFFFAOYSA-N 0.000 claims 3
- 229940115480 Histamine H3 receptor antagonist Drugs 0.000 claims 3
- 206010022489 Insulin Resistance Diseases 0.000 claims 3
- 102000000853 LDL receptors Human genes 0.000 claims 3
- 108010001831 LDL receptors Proteins 0.000 claims 3
- 102000016267 Leptin Human genes 0.000 claims 3
- 108010092277 Leptin Proteins 0.000 claims 3
- 208000017170 Lipid metabolism disease Diseases 0.000 claims 3
- 241000124008 Mammalia Species 0.000 claims 3
- 239000000637 Melanocyte-Stimulating Hormone Substances 0.000 claims 3
- 108010007013 Melanocyte-Stimulating Hormones Proteins 0.000 claims 3
- 101710151321 Melanostatin Proteins 0.000 claims 3
- 102400000064 Neuropeptide Y Human genes 0.000 claims 3
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 claims 3
- 208000008589 Obesity Diseases 0.000 claims 3
- 102000023984 PPAR alpha Human genes 0.000 claims 3
- 108010016731 PPAR gamma Proteins 0.000 claims 3
- 108010044210 PPAR-beta Proteins 0.000 claims 3
- 102100038825 Peroxisome proliferator-activated receptor gamma Human genes 0.000 claims 3
- 229940100389 Sulfonylurea Drugs 0.000 claims 3
- 230000002159 abnormal effect Effects 0.000 claims 3
- 230000009102 absorption Effects 0.000 claims 3
- 239000000048 adrenergic agonist Substances 0.000 claims 3
- 229940126157 adrenergic receptor agonist Drugs 0.000 claims 3
- 239000003888 alpha glucosidase inhibitor Substances 0.000 claims 3
- 239000002333 angiotensin II receptor antagonist Substances 0.000 claims 3
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 claims 3
- 239000003524 antilipemic agent Substances 0.000 claims 3
- 229940127218 antiplatelet drug Drugs 0.000 claims 3
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 3
- 229940097320 beta blocking agent Drugs 0.000 claims 3
- 229960000516 bezafibrate Drugs 0.000 claims 3
- IIBYAHWJQTYFKB-UHFFFAOYSA-N bezafibrate Chemical compound C1=CC(OC(C)(C)C(O)=O)=CC=C1CCNC(=O)C1=CC=C(Cl)C=C1 IIBYAHWJQTYFKB-UHFFFAOYSA-N 0.000 claims 3
- DNDCVAGJPBKION-DOPDSADYSA-N bombesin Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(N)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC=1NC2=CC=CC=C2C=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1NC(=O)CC1)C(C)C)C1=CN=CN1 DNDCVAGJPBKION-DOPDSADYSA-N 0.000 claims 3
- 230000015556 catabolic process Effects 0.000 claims 3
- 230000007870 cholestasis Effects 0.000 claims 3
- 231100000359 cholestasis Toxicity 0.000 claims 3
- 235000012000 cholesterol Nutrition 0.000 claims 3
- 229960001214 clofibrate Drugs 0.000 claims 3
- KNHUKKLJHYUCFP-UHFFFAOYSA-N clofibrate Chemical compound CCOC(=O)C(C)(C)OC1=CC=C(Cl)C=C1 KNHUKKLJHYUCFP-UHFFFAOYSA-N 0.000 claims 3
- FDJOLVPMNUYSCM-UVKKECPRSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2,7, Chemical compound [Co+3].N#[C-].C1([C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)[N-]\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O FDJOLVPMNUYSCM-UVKKECPRSA-L 0.000 claims 3
- 229960000258 corticotropin Drugs 0.000 claims 3
- IDLFZVILOHSSID-OVLDLUHVSA-N corticotropin Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)NC(=O)[C@@H](N)CO)C1=CC=C(O)C=C1 IDLFZVILOHSSID-OVLDLUHVSA-N 0.000 claims 3
- 229960004597 dexfenfluramine Drugs 0.000 claims 3
- 206010012601 diabetes mellitus Diseases 0.000 claims 3
- 229960004890 diethylpropion Drugs 0.000 claims 3
- XXEPPPIWZFICOJ-UHFFFAOYSA-N diethylpropion Chemical compound CCN(CC)C(C)C(=O)C1=CC=CC=C1 XXEPPPIWZFICOJ-UHFFFAOYSA-N 0.000 claims 3
- DLNKOYKMWOXYQA-UHFFFAOYSA-N dl-pseudophenylpropanolamine Natural products CC(N)C(O)C1=CC=CC=C1 DLNKOYKMWOXYQA-UHFFFAOYSA-N 0.000 claims 3
- 229960003638 dopamine Drugs 0.000 claims 3
- 239000002288 dopamine 2 receptor stimulating agent Substances 0.000 claims 3
- 230000003028 elevating effect Effects 0.000 claims 3
- 229960001582 fenfluramine Drugs 0.000 claims 3
- 229960002297 fenofibrate Drugs 0.000 claims 3
- YMTINGFKWWXKFG-UHFFFAOYSA-N fenofibrate Chemical compound C1=CC(OC(C)(C)C(=O)OC(C)C)=CC=C1C(=O)C1=CC=C(Cl)C=C1 YMTINGFKWWXKFG-UHFFFAOYSA-N 0.000 claims 3
- 229940125753 fibrate Drugs 0.000 claims 3
- 239000002319 fibrinogen receptor antagonist Substances 0.000 claims 3
- 230000002496 gastric effect Effects 0.000 claims 3
- 229960003627 gemfibrozil Drugs 0.000 claims 3
- 239000003382 histamine H3 receptor agonist Substances 0.000 claims 3
- 239000003395 histamine H3 receptor antagonist Substances 0.000 claims 3
- 201000001421 hyperglycemia Diseases 0.000 claims 3
- 239000000411 inducer Substances 0.000 claims 3
- NRYBAZVQPHGZNS-ZSOCWYAHSA-N leptin Chemical compound O=C([C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CC(C)C)CCSC)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CS)C(O)=O NRYBAZVQPHGZNS-ZSOCWYAHSA-N 0.000 claims 3
- 229940039781 leptin Drugs 0.000 claims 3
- 230000004060 metabolic process Effects 0.000 claims 3
- SLZIZIJTGAYEKK-CIJSCKBQSA-N molport-023-220-247 Chemical compound C([C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)CN)[C@@H](C)O)C1=CNC=N1 SLZIZIJTGAYEKK-CIJSCKBQSA-N 0.000 claims 3
- 235000005152 nicotinamide Nutrition 0.000 claims 3
- 239000011570 nicotinamide Substances 0.000 claims 3
- 229960003966 nicotinamide Drugs 0.000 claims 3
- 229960003512 nicotinic acid Drugs 0.000 claims 3
- 235000001968 nicotinic acid Nutrition 0.000 claims 3
- 239000011664 nicotinic acid Substances 0.000 claims 3
- URPYMXQQVHTUDU-OFGSCBOVSA-N nucleopeptide y Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(N)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=C(O)C=C1 URPYMXQQVHTUDU-OFGSCBOVSA-N 0.000 claims 3
- 235000020824 obesity Nutrition 0.000 claims 3
- 108091008725 peroxisome proliferator-activated receptors alpha Proteins 0.000 claims 3
- 229960003562 phentermine Drugs 0.000 claims 3
- 229960000395 phenylpropanolamine Drugs 0.000 claims 3
- DLNKOYKMWOXYQA-APPZFPTMSA-N phenylpropanolamine Chemical compound C[C@@H](N)[C@H](O)C1=CC=CC=C1 DLNKOYKMWOXYQA-APPZFPTMSA-N 0.000 claims 3
- 239000000106 platelet aggregation inhibitor Substances 0.000 claims 3
- 229960003611 pramlintide Drugs 0.000 claims 3
- 108010029667 pramlintide Proteins 0.000 claims 3
- NRKVKVQDUCJPIZ-MKAGXXMWSA-N pramlintide acetate Chemical compound C([C@@H](C(=O)NCC(=O)N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CS)NC(=O)[C@@H](N)CCCCN)[C@@H](C)O)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 NRKVKVQDUCJPIZ-MKAGXXMWSA-N 0.000 claims 3
- FYPMFJGVHOHGLL-UHFFFAOYSA-N probucol Chemical compound C=1C(C(C)(C)C)=C(O)C(C(C)(C)C)=CC=1SC(C)(C)SC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 FYPMFJGVHOHGLL-UHFFFAOYSA-N 0.000 claims 3
- 229960003912 probucol Drugs 0.000 claims 3
- GZUITABIAKMVPG-UHFFFAOYSA-N raloxifene Chemical compound C1=CC(O)=CC=C1C1=C(C(=O)C=2C=CC(OCCN3CCCCC3)=CC=2)C2=CC=C(O)C=C2S1 GZUITABIAKMVPG-UHFFFAOYSA-N 0.000 claims 3
- 229960004622 raloxifene Drugs 0.000 claims 3
- 239000002464 receptor antagonist Substances 0.000 claims 3
- 229940044551 receptor antagonist Drugs 0.000 claims 3
- 239000003488 releasing hormone Substances 0.000 claims 3
- 230000028327 secretion Effects 0.000 claims 3
- 229960004425 sibutramine Drugs 0.000 claims 3
- UNAANXDKBXWMLN-UHFFFAOYSA-N sibutramine Chemical compound C=1C=C(Cl)C=CC=1C1(C(N(C)C)CC(C)C)CCC1 UNAANXDKBXWMLN-UHFFFAOYSA-N 0.000 claims 3
- YROXIXLRRCOBKF-UHFFFAOYSA-N sulfonylurea Chemical class OC(=N)N=S(=O)=O YROXIXLRRCOBKF-UHFFFAOYSA-N 0.000 claims 3
- 208000011580 syndromic disease Diseases 0.000 claims 3
- 238000003786 synthesis reaction Methods 0.000 claims 3
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 claims 3
- 229940046728 tumor necrosis factor alpha inhibitor Drugs 0.000 claims 3
- 239000002452 tumor necrosis factor alpha inhibitor Substances 0.000 claims 3
- -1 —R 9 —C (J) R 13 Chemical group 0.000 claims 3
- ZOBPZXTWZATXDG-UHFFFAOYSA-N 1,3-thiazolidine-2,4-dione Chemical compound O=C1CSC(=O)N1 ZOBPZXTWZATXDG-UHFFFAOYSA-N 0.000 claims 2
- ITZMJCSORYKOSI-AJNGGQMLSA-N APGPR Enterostatin Chemical compound C[C@H](N)C(=O)N1CCC[C@H]1C(=O)NCC(=O)N1[C@H](C(=O)N[C@@H](CCCN=C(N)N)C(O)=O)CCC1 ITZMJCSORYKOSI-AJNGGQMLSA-N 0.000 claims 2
- 101710129690 Angiotensin-converting enzyme inhibitor Proteins 0.000 claims 2
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 claims 2
- 102100038495 Bile acid receptor Human genes 0.000 claims 2
- 101710086378 Bradykinin-potentiating and C-type natriuretic peptides Proteins 0.000 claims 2
- 102100025841 Cholecystokinin Human genes 0.000 claims 2
- 101800001982 Cholecystokinin Proteins 0.000 claims 2
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims 2
- 101000783577 Dendroaspis angusticeps Thrombostatin Proteins 0.000 claims 2
- 101000783578 Dendroaspis jamesoni kaimosae Dendroaspin Proteins 0.000 claims 2
- 208000032928 Dyslipidaemia Diseases 0.000 claims 2
- 101000603876 Homo sapiens Bile acid receptor Proteins 0.000 claims 2
- 229940127470 Lipase Inhibitors Drugs 0.000 claims 2
- 206010049287 Lipodystrophy acquired Diseases 0.000 claims 2
- 102100030817 Liver carboxylesterase 1 Human genes 0.000 claims 2
- 101710181187 Liver carboxylesterase 1 Proteins 0.000 claims 2
- ZPXSCAKFGYXMGA-UHFFFAOYSA-N Mazindol Chemical compound N12CCN=C2C2=CC=CC=C2C1(O)C1=CC=C(Cl)C=C1 ZPXSCAKFGYXMGA-UHFFFAOYSA-N 0.000 claims 2
- 108020005497 Nuclear hormone receptor Proteins 0.000 claims 2
- 229940123464 Thiazolidinedione Drugs 0.000 claims 2
- DZGWFCGJZKJUFP-UHFFFAOYSA-N Tyramine Natural products NCCC1=CC=C(O)C=C1 DZGWFCGJZKJUFP-UHFFFAOYSA-N 0.000 claims 2
- 229930003268 Vitamin C Natural products 0.000 claims 2
- 229930003427 Vitamin E Natural products 0.000 claims 2
- 229960001138 acetylsalicylic acid Drugs 0.000 claims 2
- 239000003529 anticholesteremic agent Substances 0.000 claims 2
- 229940125708 antidiabetic agent Drugs 0.000 claims 2
- 239000003472 antidiabetic agent Substances 0.000 claims 2
- 230000003143 atherosclerotic effect Effects 0.000 claims 2
- 229940107137 cholecystokinin Drugs 0.000 claims 2
- 230000029142 excretion Effects 0.000 claims 2
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims 2
- 229910052736 halogen Inorganic materials 0.000 claims 2
- 150000002367 halogens Chemical class 0.000 claims 2
- 125000001841 imino group Chemical group [H]N=* 0.000 claims 2
- 208000006132 lipodystrophy Diseases 0.000 claims 2
- 229960000299 mazindol Drugs 0.000 claims 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 2
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 claims 2
- 102000006255 nuclear receptors Human genes 0.000 claims 2
- 108020004017 nuclear receptors Proteins 0.000 claims 2
- 230000002265 prevention Effects 0.000 claims 2
- 108010070701 procolipase Proteins 0.000 claims 2
- 230000009103 reabsorption Effects 0.000 claims 2
- IZTQOLKUZKXIRV-YRVFCXMDSA-N sincalide Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](N)CC(O)=O)C1=CC=C(OS(O)(=O)=O)C=C1 IZTQOLKUZKXIRV-YRVFCXMDSA-N 0.000 claims 2
- 208000024891 symptom Diseases 0.000 claims 2
- 229960003732 tyramine Drugs 0.000 claims 2
- DZGWFCGJZKJUFP-UHFFFAOYSA-O tyraminium Chemical compound [NH3+]CCC1=CC=C(O)C=C1 DZGWFCGJZKJUFP-UHFFFAOYSA-O 0.000 claims 2
- 235000019154 vitamin C Nutrition 0.000 claims 2
- 239000011718 vitamin C Substances 0.000 claims 2
- 235000019165 vitamin E Nutrition 0.000 claims 2
- 229940046009 vitamin E Drugs 0.000 claims 2
- 239000011709 vitamin E Substances 0.000 claims 2
- GCVLCLFIEOVLMG-UHFFFAOYSA-N 2-(3-acetylphenyl)imino-5-(2,3-dihydroindol-1-ylmethylidene)-3-(furan-2-ylmethyl)-1,3-thiazolidin-4-one Chemical compound CC(=O)C1=CC=CC(N=C2N(C(=O)C(=CN3C4=CC=CC=C4CC3)S2)CC=2OC=CC=2)=C1 GCVLCLFIEOVLMG-UHFFFAOYSA-N 0.000 claims 1
- UEKDOPPDCYNGHM-UHFFFAOYSA-N 2-[5-acetyl-2-(ethylamino)phenyl]imino-3,5-dibenzyl-1,3-thiazolidin-4-one Chemical compound CCNC1=CC=C(C(C)=O)C=C1N=C1N(CC=2C=CC=CC=2)C(=O)C(CC=2C=CC=CC=2)S1 UEKDOPPDCYNGHM-UHFFFAOYSA-N 0.000 claims 1
- HLSDYWFUKOZJTE-UHFFFAOYSA-N 2-[5-acetyl-2-(ethylamino)phenyl]imino-3-benzyl-5-(2,3-dihydroindol-1-ylmethylidene)-1,3-thiazolidin-4-one Chemical compound CCNC1=CC=C(C(C)=O)C=C1N=C(S1)N(CC=2C=CC=CC=2)C(=O)C1=CN1C2=CC=CC=C2CC1 HLSDYWFUKOZJTE-UHFFFAOYSA-N 0.000 claims 1
- UYOKDJNIHORDNT-UHFFFAOYSA-N 2-[5-acetyl-2-(ethylamino)phenyl]imino-3-benzyl-5-(2-phenylethyl)-1,3-thiazolidin-4-one Chemical compound CCNC1=CC=C(C(C)=O)C=C1N=C1N(CC=2C=CC=CC=2)C(=O)C(CCC=2C=CC=CC=2)S1 UYOKDJNIHORDNT-UHFFFAOYSA-N 0.000 claims 1
- QRMFPGOYLMAMMW-UHFFFAOYSA-N 2-[5-acetyl-2-(ethylamino)phenyl]imino-3-benzyl-5-(dimethylaminomethylidene)-1,3-thiazolidin-4-one Chemical compound CCNC1=CC=C(C(C)=O)C=C1N=C1N(CC=2C=CC=CC=2)C(=O)C(=CN(C)C)S1 QRMFPGOYLMAMMW-UHFFFAOYSA-N 0.000 claims 1
- PZCIROBDGVLEIL-UHFFFAOYSA-N 2-[5-acetyl-2-(ethylamino)phenyl]imino-3-benzyl-5-(furan-2-ylmethylidene)-1,3-thiazolidin-4-one Chemical compound CCNC1=CC=C(C(C)=O)C=C1N=C(S1)N(CC=2C=CC=CC=2)C(=O)C1=CC1=CC=CO1 PZCIROBDGVLEIL-UHFFFAOYSA-N 0.000 claims 1
- PDXNFKUZVGOMRC-UHFFFAOYSA-N 2-[5-acetyl-2-(ethylamino)phenyl]imino-3-benzyl-5-[(3-methoxy-n-methylanilino)methylidene]-1,3-thiazolidin-4-one Chemical compound CCNC1=CC=C(C(C)=O)C=C1N=C(S1)N(CC=2C=CC=CC=2)C(=O)C1=CN(C)C1=CC=CC(OC)=C1 PDXNFKUZVGOMRC-UHFFFAOYSA-N 0.000 claims 1
- OMZSQHXDIDHBFC-UHFFFAOYSA-N 2-[5-acetyl-2-(ethylamino)phenyl]imino-3-benzyl-5-[(4-methoxy-n-methylanilino)methylidene]-1,3-thiazolidin-4-one Chemical compound CCNC1=CC=C(C(C)=O)C=C1N=C(S1)N(CC=2C=CC=CC=2)C(=O)C1=CN(C)C1=CC=C(OC)C=C1 OMZSQHXDIDHBFC-UHFFFAOYSA-N 0.000 claims 1
- ZWQHCOQRXKFJGB-UHFFFAOYSA-N 2-[5-acetyl-2-(ethylamino)phenyl]imino-3-benzyl-5-[(4-methylpiperazin-1-yl)methylidene]-1,3-thiazolidin-4-one Chemical compound CCNC1=CC=C(C(C)=O)C=C1N=C(S1)N(CC=2C=CC=CC=2)C(=O)C1=CN1CCN(C)CC1 ZWQHCOQRXKFJGB-UHFFFAOYSA-N 0.000 claims 1
- VZGIJCXVUUINRV-UHFFFAOYSA-N 2-[5-acetyl-2-(ethylamino)phenyl]imino-3-benzyl-5-[(n-methylanilino)methylidene]-1,3-thiazolidin-4-one Chemical compound CCNC1=CC=C(C(C)=O)C=C1N=C(S1)N(CC=2C=CC=CC=2)C(=O)C1=CN(C)C1=CC=CC=C1 VZGIJCXVUUINRV-UHFFFAOYSA-N 0.000 claims 1
- KNPWYRGLLCQAQC-UHFFFAOYSA-N 2-[5-acetyl-2-(ethylamino)phenyl]imino-3-benzyl-5-[[3-(dimethylamino)propyl-methylamino]methylidene]-1,3-thiazolidin-4-one Chemical compound CCNC1=CC=C(C(C)=O)C=C1N=C1N(CC=2C=CC=CC=2)C(=O)C(=CN(C)CCCN(C)C)S1 KNPWYRGLLCQAQC-UHFFFAOYSA-N 0.000 claims 1
- XABCMNNTHFJDCF-UHFFFAOYSA-N 2-[5-acetyl-2-(ethylamino)phenyl]imino-3-benzyl-5-[[4-(2-methoxyethoxy)-n-methylanilino]methylidene]-1,3-thiazolidin-4-one Chemical compound CCNC1=CC=C(C(C)=O)C=C1N=C(S1)N(CC=2C=CC=CC=2)C(=O)C1=CN(C)C1=CC=C(OCCOC)C=C1 XABCMNNTHFJDCF-UHFFFAOYSA-N 0.000 claims 1
- BZXKLXUWHZDDTA-UHFFFAOYSA-N 2-[5-acetyl-2-(ethylamino)phenyl]imino-3-benzyl-5-[[benzyl(methyl)amino]methylidene]-1,3-thiazolidin-4-one Chemical compound CCNC1=CC=C(C(C)=O)C=C1N=C(S1)N(CC=2C=CC=CC=2)C(=O)C1=CN(C)CC1=CC=CC=C1 BZXKLXUWHZDDTA-UHFFFAOYSA-N 0.000 claims 1
- GMUCPXKPCHHGMW-UHFFFAOYSA-N 2-[5-acetyl-2-(ethylamino)phenyl]imino-3-benzyl-5-[[methyl(2-phenylethyl)amino]methylidene]-1,3-thiazolidin-4-one Chemical compound CCNC1=CC=C(C(C)=O)C=C1N=C(S1)N(CC=2C=CC=CC=2)C(=O)C1=CN(C)CCC1=CC=CC=C1 GMUCPXKPCHHGMW-UHFFFAOYSA-N 0.000 claims 1
- KYXHFHACYVKHAB-UHFFFAOYSA-N 2-[5-acetyl-2-(ethylamino)phenyl]imino-3-benzyl-5-benzylidene-1,3-thiazolidin-4-one Chemical compound CCNC1=CC=C(C(C)=O)C=C1N=C(S1)N(CC=2C=CC=CC=2)C(=O)C1=CC1=CC=CC=C1 KYXHFHACYVKHAB-UHFFFAOYSA-N 0.000 claims 1
- FTTCNMOCBHYESC-UHFFFAOYSA-N 2-[5-acetyl-2-(ethylamino)phenyl]imino-3-benzyl-5-phenacyl-1,3-thiazolidin-4-one Chemical compound CCNC1=CC=C(C(C)=O)C=C1N=C1N(CC=2C=CC=CC=2)C(=O)C(CC(=O)C=2C=CC=CC=2)S1 FTTCNMOCBHYESC-UHFFFAOYSA-N 0.000 claims 1
- HKFQHSDEEUNRTI-UHFFFAOYSA-N 3-[[3-benzyl-5-(2,3-dihydroindol-1-ylmethylidene)-4-oxo-1,3-thiazolidin-2-ylidene]amino]-4-(ethylamino)benzonitrile Chemical compound CCNC1=CC=C(C#N)C=C1N=C(S1)N(CC=2C=CC=CC=2)C(=O)C1=CN1C2=CC=CC=C2CC1 HKFQHSDEEUNRTI-UHFFFAOYSA-N 0.000 claims 1
- ZQWBBJKQQQLRBO-UHFFFAOYSA-N 3-[[3-benzyl-5-(dimethylaminomethylidene)-4-oxo-1,3-thiazolidin-2-ylidene]amino]-4-(ethylamino)benzonitrile Chemical compound CCNC1=CC=C(C#N)C=C1N=C1N(CC=2C=CC=CC=2)C(=O)C(=CN(C)C)S1 ZQWBBJKQQQLRBO-UHFFFAOYSA-N 0.000 claims 1
- VOGNACRDQCXWGA-UHFFFAOYSA-N 3-[[3-benzyl-5-[(2-methoxy-n-methylanilino)methylidene]-4-oxo-1,3-thiazolidin-2-ylidene]amino]-4-(ethylamino)benzonitrile Chemical compound CCNC1=CC=C(C#N)C=C1N=C(S1)N(CC=2C=CC=CC=2)C(=O)C1=CN(C)C1=CC=CC=C1OC VOGNACRDQCXWGA-UHFFFAOYSA-N 0.000 claims 1
- FRRBVAOXYDQYKI-UHFFFAOYSA-N 3-[[3-benzyl-5-[(4-methoxyanilino)methylidene]-4-oxo-1,3-thiazolidin-2-ylidene]amino]-4-(ethylamino)benzonitrile Chemical compound CCNC1=CC=C(C#N)C=C1N=C(S1)N(CC=2C=CC=CC=2)C(=O)C1=CNC1=CC=C(OC)C=C1 FRRBVAOXYDQYKI-UHFFFAOYSA-N 0.000 claims 1
- MHGFLCUKXSCYJV-UHFFFAOYSA-N 3-[[3-benzyl-5-[(n-methylanilino)methylidene]-4-oxo-1,3-thiazolidin-2-ylidene]amino]-4-(ethylamino)benzonitrile Chemical compound CCNC1=CC=C(C#N)C=C1N=C(S1)N(CC=2C=CC=CC=2)C(=O)C1=CN(C)C1=CC=CC=C1 MHGFLCUKXSCYJV-UHFFFAOYSA-N 0.000 claims 1
- DXNSGASFGISSOY-UHFFFAOYSA-N 3-[[3-benzyl-5-[[benzyl(methyl)amino]methylidene]-4-oxo-1,3-thiazolidin-2-ylidene]amino]-4-(ethylamino)benzonitrile Chemical compound CCNC1=CC=C(C#N)C=C1N=C(S1)N(CC=2C=CC=CC=2)C(=O)C1=CN(C)CC1=CC=CC=C1 DXNSGASFGISSOY-UHFFFAOYSA-N 0.000 claims 1
- OCVLSHAVSIYKLI-UHFFFAOYSA-N 3h-1,3-thiazole-2-thione Chemical compound SC1=NC=CS1 OCVLSHAVSIYKLI-UHFFFAOYSA-N 0.000 claims 1
- 125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 claims 1
- NQQMUAALTMRXKD-WOARFCOISA-N C1=CC(NC(=O)C)=CC=C1\N=C(/S\1)N(CC=2OC=CC=2)C(=O)C/1=C/N1C2=CC=CC=C2CC1 Chemical compound C1=CC(NC(=O)C)=CC=C1\N=C(/S\1)N(CC=2OC=CC=2)C(=O)C/1=C/N1C2=CC=CC=C2CC1 NQQMUAALTMRXKD-WOARFCOISA-N 0.000 claims 1
- GCVLCLFIEOVLMG-JTUXUYRKSA-N CC(=O)C1=CC=CC(\N=C/2N(C(=O)C(=C/N3C4=CC=CC=C4CC3)/S\2)CC=2OC=CC=2)=C1 Chemical compound CC(=O)C1=CC=CC(\N=C/2N(C(=O)C(=C/N3C4=CC=CC=C4CC3)/S\2)CC=2OC=CC=2)=C1 GCVLCLFIEOVLMG-JTUXUYRKSA-N 0.000 claims 1
- DXNSGASFGISSOY-QMIAEUBZSA-N CCNC1=CC=C(C#N)C=C1\N=C(/S\1)N(CC=2C=CC=CC=2)C(=O)C/1=C/N(C)CC1=CC=CC=C1 Chemical compound CCNC1=CC=C(C#N)C=C1\N=C(/S\1)N(CC=2C=CC=CC=2)C(=O)C/1=C/N(C)CC1=CC=CC=C1 DXNSGASFGISSOY-QMIAEUBZSA-N 0.000 claims 1
- HKFQHSDEEUNRTI-LKNIRPGHSA-N CCNC1=CC=C(C#N)C=C1\N=C(/S\1)N(CC=2C=CC=CC=2)C(=O)C/1=C/N1C2=CC=CC=C2CC1 Chemical compound CCNC1=CC=C(C#N)C=C1\N=C(/S\1)N(CC=2C=CC=CC=2)C(=O)C/1=C/N1C2=CC=CC=C2CC1 HKFQHSDEEUNRTI-LKNIRPGHSA-N 0.000 claims 1
- FRRBVAOXYDQYKI-ICDTUWNZSA-N CCNC1=CC=C(C#N)C=C1\N=C(/S\1)N(CC=2C=CC=CC=2)C(=O)C/1=C/NC1=CC=C(OC)C=C1 Chemical compound CCNC1=CC=C(C#N)C=C1\N=C(/S\1)N(CC=2C=CC=CC=2)C(=O)C/1=C/NC1=CC=C(OC)C=C1 FRRBVAOXYDQYKI-ICDTUWNZSA-N 0.000 claims 1
- ZQWBBJKQQQLRBO-YWNZOVFCSA-N CCNC1=CC=C(C#N)C=C1\N=C/1N(CC=2C=CC=CC=2)C(=O)C(=C/N(C)C)/S\1 Chemical compound CCNC1=CC=C(C#N)C=C1\N=C/1N(CC=2C=CC=CC=2)C(=O)C(=C/N(C)C)/S\1 ZQWBBJKQQQLRBO-YWNZOVFCSA-N 0.000 claims 1
- KYXHFHACYVKHAB-YMURDISESA-N CCNC1=CC=C(C(C)=O)C=C1\N=C(/S\1)N(CC=2C=CC=CC=2)C(=O)C/1=C/C1=CC=CC=C1 Chemical compound CCNC1=CC=C(C(C)=O)C=C1\N=C(/S\1)N(CC=2C=CC=CC=2)C(=O)C/1=C/C1=CC=CC=C1 KYXHFHACYVKHAB-YMURDISESA-N 0.000 claims 1
- PZCIROBDGVLEIL-KHHYFDFNSA-N CCNC1=CC=C(C(C)=O)C=C1\N=C(/S\1)N(CC=2C=CC=CC=2)C(=O)C/1=C/C1=CC=CO1 Chemical compound CCNC1=CC=C(C(C)=O)C=C1\N=C(/S\1)N(CC=2C=CC=CC=2)C(=O)C/1=C/C1=CC=CO1 PZCIROBDGVLEIL-KHHYFDFNSA-N 0.000 claims 1
- XABCMNNTHFJDCF-GVZJHPDTSA-N CCNC1=CC=C(C(C)=O)C=C1\N=C(/S\1)N(CC=2C=CC=CC=2)C(=O)C/1=C/N(C)C1=CC=C(OCCOC)C=C1 Chemical compound CCNC1=CC=C(C(C)=O)C=C1\N=C(/S\1)N(CC=2C=CC=CC=2)C(=O)C/1=C/N(C)C1=CC=C(OCCOC)C=C1 XABCMNNTHFJDCF-GVZJHPDTSA-N 0.000 claims 1
- PDXNFKUZVGOMRC-BOTKPODPSA-N CCNC1=CC=C(C(C)=O)C=C1\N=C(/S\1)N(CC=2C=CC=CC=2)C(=O)C/1=C/N(C)C1=CC=CC(OC)=C1 Chemical compound CCNC1=CC=C(C(C)=O)C=C1\N=C(/S\1)N(CC=2C=CC=CC=2)C(=O)C/1=C/N(C)C1=CC=CC(OC)=C1 PDXNFKUZVGOMRC-BOTKPODPSA-N 0.000 claims 1
- VZGIJCXVUUINRV-GWVUPHRNSA-N CCNC1=CC=C(C(C)=O)C=C1\N=C(/S\1)N(CC=2C=CC=CC=2)C(=O)C/1=C/N(C)C1=CC=CC=C1 Chemical compound CCNC1=CC=C(C(C)=O)C=C1\N=C(/S\1)N(CC=2C=CC=CC=2)C(=O)C/1=C/N(C)C1=CC=CC=C1 VZGIJCXVUUINRV-GWVUPHRNSA-N 0.000 claims 1
- BZXKLXUWHZDDTA-DINUBHSRSA-N CCNC1=CC=C(C(C)=O)C=C1\N=C(/S\1)N(CC=2C=CC=CC=2)C(=O)C/1=C/N(C)CC1=CC=CC=C1 Chemical compound CCNC1=CC=C(C(C)=O)C=C1\N=C(/S\1)N(CC=2C=CC=CC=2)C(=O)C/1=C/N(C)CC1=CC=CC=C1 BZXKLXUWHZDDTA-DINUBHSRSA-N 0.000 claims 1
- GMUCPXKPCHHGMW-ATKAZLLPSA-N CCNC1=CC=C(C(C)=O)C=C1\N=C(/S\1)N(CC=2C=CC=CC=2)C(=O)C/1=C/N(C)CCC1=CC=CC=C1 Chemical compound CCNC1=CC=C(C(C)=O)C=C1\N=C(/S\1)N(CC=2C=CC=CC=2)C(=O)C/1=C/N(C)CCC1=CC=CC=C1 GMUCPXKPCHHGMW-ATKAZLLPSA-N 0.000 claims 1
- HLSDYWFUKOZJTE-BOTKPODPSA-N CCNC1=CC=C(C(C)=O)C=C1\N=C(/S\1)N(CC=2C=CC=CC=2)C(=O)C/1=C/N1C2=CC=CC=C2CC1 Chemical compound CCNC1=CC=C(C(C)=O)C=C1\N=C(/S\1)N(CC=2C=CC=CC=2)C(=O)C/1=C/N1C2=CC=CC=C2CC1 HLSDYWFUKOZJTE-BOTKPODPSA-N 0.000 claims 1
- ZWQHCOQRXKFJGB-ULVCWHGLSA-N CCNC1=CC=C(C(C)=O)C=C1\N=C(/S\1)N(CC=2C=CC=CC=2)C(=O)C/1=C/N1CCN(C)CC1 Chemical compound CCNC1=CC=C(C(C)=O)C=C1\N=C(/S\1)N(CC=2C=CC=CC=2)C(=O)C/1=C/N1CCN(C)CC1 ZWQHCOQRXKFJGB-ULVCWHGLSA-N 0.000 claims 1
- QRMFPGOYLMAMMW-YVADOFBFSA-N CCNC1=CC=C(C(C)=O)C=C1\N=C/1N(CC=2C=CC=CC=2)C(=O)C(=C/N(C)C)/S\1 Chemical compound CCNC1=CC=C(C(C)=O)C=C1\N=C/1N(CC=2C=CC=CC=2)C(=O)C(=C/N(C)C)/S\1 QRMFPGOYLMAMMW-YVADOFBFSA-N 0.000 claims 1
- FTTCNMOCBHYESC-HYOGKJQXSA-N CCNC1=CC=C(C(C)=O)C=C1\N=C/1N(CC=2C=CC=CC=2)C(=O)C(CC(=O)C=2C=CC=CC=2)S\1 Chemical compound CCNC1=CC=C(C(C)=O)C=C1\N=C/1N(CC=2C=CC=CC=2)C(=O)C(CC(=O)C=2C=CC=CC=2)S\1 FTTCNMOCBHYESC-HYOGKJQXSA-N 0.000 claims 1
- UEKDOPPDCYNGHM-OHYPFYFLSA-N CCNC1=CC=C(C(C)=O)C=C1\N=C/1N(CC=2C=CC=CC=2)C(=O)C(CC=2C=CC=CC=2)S\1 Chemical compound CCNC1=CC=C(C(C)=O)C=C1\N=C/1N(CC=2C=CC=CC=2)C(=O)C(CC=2C=CC=CC=2)S\1 UEKDOPPDCYNGHM-OHYPFYFLSA-N 0.000 claims 1
- UYOKDJNIHORDNT-HYOGKJQXSA-N CCNC1=CC=C(C(C)=O)C=C1\N=C/1N(CC=2C=CC=CC=2)C(=O)C(CCC=2C=CC=CC=2)S\1 Chemical compound CCNC1=CC=C(C(C)=O)C=C1\N=C/1N(CC=2C=CC=CC=2)C(=O)C(CCC=2C=CC=CC=2)S\1 UYOKDJNIHORDNT-HYOGKJQXSA-N 0.000 claims 1
- FMGSKLZLMKYGDP-UHFFFAOYSA-N Dehydroepiandrosterone Natural products C1C(O)CCC2(C)C3CCC(C)(C(CC4)=O)C4C3CC=C21 FMGSKLZLMKYGDP-UHFFFAOYSA-N 0.000 claims 1
- 229940122206 Farnesoid X receptor antagonist Drugs 0.000 claims 1
- 229940086609 Lipase inhibitor Drugs 0.000 claims 1
- 102000001494 Sterol O-Acyltransferase Human genes 0.000 claims 1
- 108010054082 Sterol O-acyltransferase Proteins 0.000 claims 1
- 230000003178 anti-diabetic effect Effects 0.000 claims 1
- 239000003963 antioxidant agent Substances 0.000 claims 1
- 230000003078 antioxidant effect Effects 0.000 claims 1
- 235000006708 antioxidants Nutrition 0.000 claims 1
- 229940125388 beta agonist Drugs 0.000 claims 1
- 210000000941 bile Anatomy 0.000 claims 1
- RGJOEKWQDUBAIZ-UHFFFAOYSA-N coenzime A Natural products OC1C(OP(O)(O)=O)C(COP(O)(=O)OP(O)(=O)OCC(C)(C)C(O)C(=O)NCCC(=O)NCCS)OC1N1C2=NC=NC(N)=C2N=C1 RGJOEKWQDUBAIZ-UHFFFAOYSA-N 0.000 claims 1
- 239000005516 coenzyme A Substances 0.000 claims 1
- 229940093530 coenzyme a Drugs 0.000 claims 1
- UQHKFADEQIVWID-UHFFFAOYSA-N cytokinin Natural products C1=NC=2C(NCC=C(CO)C)=NC=NC=2N1C1CC(O)C(CO)O1 UQHKFADEQIVWID-UHFFFAOYSA-N 0.000 claims 1
- 239000004062 cytokinin Substances 0.000 claims 1
- FMGSKLZLMKYGDP-USOAJAOKSA-N dehydroepiandrosterone Chemical compound C1[C@@H](O)CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC=C21 FMGSKLZLMKYGDP-USOAJAOKSA-N 0.000 claims 1
- KDTSHFARGAKYJN-UHFFFAOYSA-N dephosphocoenzyme A Natural products OC1C(O)C(COP(O)(=O)OP(O)(=O)OCC(C)(C)C(O)C(=O)NCCC(=O)NCCS)OC1N1C2=NC=NC(N)=C2N=C1 KDTSHFARGAKYJN-UHFFFAOYSA-N 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 229940121360 farnesoid X receptor (fxr) agonists Drugs 0.000 claims 1
- 239000003862 glucocorticoid Substances 0.000 claims 1
- NQQMUAALTMRXKD-UHFFFAOYSA-N n-[4-[[5-(2,3-dihydroindol-1-ylmethylidene)-3-(furan-2-ylmethyl)-4-oxo-1,3-thiazolidin-2-ylidene]amino]phenyl]acetamide Chemical compound C1=CC(NC(=O)C)=CC=C1N=C(S1)N(CC=2OC=CC=2)C(=O)C1=CN1C2=CC=CC=C2CC1 NQQMUAALTMRXKD-UHFFFAOYSA-N 0.000 claims 1
- 229960002847 prasterone Drugs 0.000 claims 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- 230000001603 reducing effect Effects 0.000 claims 1
- 150000003626 triacylglycerols Chemical class 0.000 claims 1
- 229930003231 vitamin Natural products 0.000 claims 1
- 235000013343 vitamin Nutrition 0.000 claims 1
- 239000011782 vitamin Substances 0.000 claims 1
- 229940088594 vitamin Drugs 0.000 claims 1
- 0 *C(N(*)*)=C(*C(N1*)=N*)C1=* Chemical compound *C(N(*)*)=C(*C(N1*)=N*)C1=* 0.000 description 3
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US60023904P | 2004-08-10 | 2004-08-10 | |
| PCT/US2005/028357 WO2006020680A2 (en) | 2004-08-10 | 2005-08-09 | Heterocyclic compounds as pharmaceutical agents |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2008509912A JP2008509912A (ja) | 2008-04-03 |
| JP2008509912A5 true JP2008509912A5 (https=) | 2008-09-25 |
Family
ID=35908114
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007525749A Pending JP2008509912A (ja) | 2004-08-10 | 2005-08-09 | 医薬品としての複素環化合物 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US7902237B2 (https=) |
| EP (1) | EP1776112A4 (https=) |
| JP (1) | JP2008509912A (https=) |
| CN (1) | CN101010078A (https=) |
| AU (1) | AU2005272916A1 (https=) |
| BR (1) | BRPI0514269A (https=) |
| CA (1) | CA2574279A1 (https=) |
| MX (1) | MX2007001539A (https=) |
| WO (1) | WO2006020680A2 (https=) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20090156644A1 (en) * | 2005-07-21 | 2009-06-18 | Jacob Westman | Use of thiazole derivatives and analogues in the treatment of cancer |
| DE102007003524A1 (de) * | 2007-01-19 | 2008-09-04 | MEDICE Arzneimittel Pütter GmbH & Co. KG | Arzneimittel zur Behandlung und/oder Prävention von Arteriosklerose |
| WO2008090356A1 (en) * | 2007-01-25 | 2008-07-31 | Betagenon Ab | Thiazolidinone derivatives useful in the treatment of cancer and disorders caused by excess adiposity |
| CN101274918A (zh) * | 2007-03-30 | 2008-10-01 | 中国科学院上海药物研究所 | 一类取代五元杂环化合物,其制备方法和医学用途 |
| WO2010086613A1 (en) | 2009-01-30 | 2010-08-05 | Betagenon Ab | Compounds useful as inhibitors as ampk |
| WO2012106581A1 (en) * | 2011-02-03 | 2012-08-09 | The University Of Chicago | Fxr inhibitor, bile acid sequestrant as combination therapy for cholesterol reduction |
| NZ734451A (en) * | 2012-06-19 | 2018-12-21 | Intercept Pharmaceuticals Inc | Preparation, uses and solid forms of obeticholic acid |
| JP6556129B2 (ja) | 2013-08-01 | 2019-08-07 | アメリカ合衆国 | ファルネソイドｘ受容体の阻害剤及び医薬としての使用 |
| SI3043865T1 (sl) | 2013-09-11 | 2021-04-30 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Metode in farmacevtski sestavki za zdravljenje virusne okužbe s hepatitisom B |
| EP2952188A1 (en) * | 2014-06-03 | 2015-12-09 | Universität Bern | Thiazolidinones as cellular anandamide uptake inhibitors and their use in the treatment of psychiatric or neurological disorders and inflammation, in particular neuroinflammation |
| EP3148541B1 (en) | 2014-05-28 | 2020-09-02 | Universität Bern | Thiazolidinones as cellular anandamide uptake inhibitors and their use in the treatment of psychiatric or neurological disorders and inflammation, in particular neuroinflammation |
| EP3715348A1 (en) | 2015-03-26 | 2020-09-30 | Akarna Therapeutics, Ltd. | Fused bicyclic compounds for the treatment of disease |
| TW201741307A (zh) * | 2016-02-22 | 2017-12-01 | 艾洛斯生物製藥公司 | Ｆｘｒ調節劑及其使用方法 |
| WO2018178260A1 (en) | 2017-03-30 | 2018-10-04 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for reducing persistence and expression of episomal viruses |
| JP2020530477A (ja) * | 2017-08-10 | 2020-10-22 | ザ テキサス エーアンドエム ユニヴァーシティ システム | Ｎｒ４ａ１リガンド、医薬組成物、及び関連する使用方法 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BE523919A (https=) * | 1952-10-31 | |||
| US2719162A (en) * | 1954-03-29 | 1955-09-27 | Eastman Kodak Co | 5-(3-hydroxybenzylidene)-3-phenyl-2-phenylimino-4-thiazolidone and process |
| US3097100A (en) * | 1960-01-25 | 1963-07-09 | Eastman Kodak Co | Thiazolidones as light stabilizers for plastic compositions |
| BE608790A (fr) | 1960-10-08 | 1962-04-03 | Kalle Ag | Matériel photosensible. |
| US3314794A (en) | 1964-05-13 | 1967-04-18 | Eastman Kodak Co | Ultraviolet absorbers |
| FR1604530A (https=) * | 1967-06-06 | 1971-11-29 | ||
| US5198454A (en) * | 1991-12-03 | 1993-03-30 | Texas A&M University System | Use of OB-104 to treat ocular inflammation |
| JPH06128234A (ja) | 1992-10-19 | 1994-05-10 | Fuji Photo Film Co Ltd | 不斉炭素原子を有する化合物およびそれからなる非線形光学材料 |
| JP3871354B2 (ja) * | 1994-07-29 | 2007-01-24 | 株式会社フジモト・コーポレーション | 新規な２−（ｎ−シアノイミノ）チアゾリジン−４−オン誘導体 |
| US6353006B1 (en) * | 1999-01-14 | 2002-03-05 | Bayer Corporation | Substituted 2-arylimino heterocycles and compositions containing them, for use as progesterone receptor binding agents |
| ES2367539T3 (es) * | 2001-12-21 | 2011-11-04 | X-Ceptor Therapeutics, Inc. | Moduladores heterocíclicos de receptores nucleares. |
-
2005
- 2005-08-09 MX MX2007001539A patent/MX2007001539A/es not_active Application Discontinuation
- 2005-08-09 EP EP05786284A patent/EP1776112A4/en not_active Withdrawn
- 2005-08-09 BR BRPI0514269-5A patent/BRPI0514269A/pt not_active IP Right Cessation
- 2005-08-09 CA CA002574279A patent/CA2574279A1/en not_active Abandoned
- 2005-08-09 CN CNA2005800272537A patent/CN101010078A/zh active Pending
- 2005-08-09 JP JP2007525749A patent/JP2008509912A/ja active Pending
- 2005-08-09 US US11/573,614 patent/US7902237B2/en not_active Expired - Fee Related
- 2005-08-09 AU AU2005272916A patent/AU2005272916A1/en not_active Abandoned
- 2005-08-09 WO PCT/US2005/028357 patent/WO2006020680A2/en not_active Ceased